Clinical Trials Browser

Phase 2 × OTHER × Alzheimer Disease × Clear all

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT06723015 2025-11-18

Tau PET Outcomes With Anti-amyloid Immunotherapies

Phase 2 Enrolling by invitation

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Phase 2 Completed

35 enrolled 9 charts

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis